scholarly journals P89 Thrombotic thrombocytopenic purpura complicating antiphospholipid antibody syndrome

2009 ◽  
Vol 4 (3) ◽  
pp. S26
Author(s):  
Ramakrishnam Naidu
Author(s):  
Arth Shah ◽  
D.C Kumawat

Immune thrombocytopenic purpura (ITP) can be both primary and secondary. The secondary form of this disease may occur in association with systemic lupus erythematosus, antiphospholipid antibody syndrome, immunodeficient states, lymphoproliferative disorders, viral infections and using drugs such as quinidine, sulfa and heparin.


1994 ◽  
Vol 71 (04) ◽  
pp. 424-427 ◽  
Author(s):  
Masahide Yamazaki ◽  
Hidesaku Asakura ◽  
Hiroshi Jokaji ◽  
Masanori Saito ◽  
Chika Uotani ◽  
...  

SummaryThe mechanisms underlying clinical abnormalities associated with the antiphospholipid antibody syndrome (APAS) have not been elucidated. We measured plasma levels of lipoprotein(a) [Lp(a)], the active form of plasminogen activator inhibitor (active PAI), thrombin-antithrombin III complex (TAT) and soluble thrombomodulin (TM), to investigate the relationship of these factors to thrombotic events in APAS. Mean plasma levels of Lp(a), TAT, active PAI and TM were all significantly higher in patients with aPL than in a control group of subjects. Plasma levels of Lp(a) and active PAI were significantly higher in patients with aPL and arterial thromboses than in patients with aPL but only venous thromboses. There was a significant correlation between plasma levels of Lp(a) and active PAI in patients with aPL. These findings suggest that patients with aPL are in hypercoagulable state. High levels of Lp(a) in plasma may impair the fibrinolytic system resulting in thromboses, especially in the arterial system.


1981 ◽  
Vol 46 (02) ◽  
pp. 571-571 ◽  
Author(s):  
M Pini ◽  
C Manotti ◽  
R Quintavalla ◽  
A G Dettori

Sign in / Sign up

Export Citation Format

Share Document